Sanofi’s Dupixent Under FDA Priority Review for Adolescents with CRSwNP

Sanofi SNY, a global biopharmaceutical company, is poised to make medical history with Dupixent^® (dupilumab) as it undergoes a U.S. FDA Priority Review. If approved, Dupixent would revolutionize treatment options for adolescents aged 12 to 17 suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). This treatment targets inadequately controlled CRSwNP, a debilitating condition characterized by type 2 inflammation, leading to sinus obstruction and the potential loss of smell.

Understanding CRSwNP and Dupilumab's Role

Chronic rhinosinusitis with nasal polyposis significantly affects the lives of many adolescents, causing persistent congestion, facial pain, and diminished sensory experiences. Dupilumab's proposed impact is particularly noteworthy because it directly addresses underlying mechanisms of type 2 inflammation, a critical factor in the pathology of CRSwNP.

Sanofi's Commitment to Innovation and Patient Care

Sanofi's dedication to developing therapeutic solutions extends beyond the borders of its Paris headquarters, impacting patients on a global scale. Through rigorous research, development, and a focus on unmet medical needs, SNY continues to demonstrate an unwavering commitment to enhancing patient outcomes and pushing the frontiers of healthcare.

Sanofi, Dupixent, FDA